- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Senores Pharma's board approved strong Q2FY26 consolidated financial results: Revenue jumped 61% to Rs 162 Cr, while PAT soared 131% to Rs 30 Cr. H1 results were also robust. Additionally, Mr. Manohar Lalge was appointed as President-R&D (SMP).